Nicoderm

PreclinicalSmall molecule

OOttawa Heart Institute Research Corporation

Nicoderm is one of 8 small molecule programs targeting Smoking. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SmokingCompleted

SmokingPreclinical

Completed

Competition

Competitive Landscape

9 competitors in Smoking

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

17 2

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

5 3

Nicotine Free Cigarettes

Pfizer

Phase 3

5 4

Nicotine Replacement

GSK

Preclinical

1 5

Nicorette

HHALEON

Preclinical

1 6

Nicotine Gum

Johnson & Johnson

Preclinical

—7

Nicotine Patches

UUniversity of California, San Diego

Preclinical

2 8

Nicoderm

OOttawa Heart Institute Research Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smoking1 trial

Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation

Completed·CCentre for Addiction and Mental Health·N/A·NCT00289653·23 enrolled

Nicotine Dependence1 trial

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

Terminated·AA. Eden Evins·Phase 2·NCT01480232·345 enrolled

Cardiovascular Disease1 trial

Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling

Completed·OOttawa Heart Institute Research Corporation·Phase 4·NCT01623505·738 enrolled

Alzheimer disease1 trial

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00018278

Efficacy1 trial

Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)

Completed·UUniversity of Pennsylvania·Phase 4·NCT00326781·674 enrolled

4 more indications

Complication1 trial

Effect of Pre-op NRT on Peri-operative Complications and Long-term Abstinence: A Pilot Trial in Patients Undergoing CABG Surgery

Terminated·OOttawa Heart Institute Research Corporation·Phase 4·NCT02918500·4 enrolled

Smokers1 trial

Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRT

Terminated·RRose Research Center, LLC·Phase 3·NCT06088862·4 enrolled

Smoking Reduction1 trial

Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders

Completed·RRose Research Center, LLC·Phase 3·NCT06554873·150 enrolled

Smoking Cessation1 trial

Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation in Smokers Motivated to Quit

Completed·OOttawa Heart Institute Research Corporation·Approved·NCT01622998·303 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Nicoderm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicoderm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicoderm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ottawa Heart Institute Research Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOttawa Heart Institute Research Corporation

Nicoderm

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smoking1 trial

Nicotine Dependence1 trial

Cardiovascular Disease1 trial

Alzheimer disease1 trial

Efficacy1 trial

Complication1 trial

Smokers1 trial

Smoking Reduction1 trial

Smoking Cessation1 trial

References

Drug Info

Quick Facts

Related News